Patent · US Active

Modified plasma clotting factor VIII and method of use thereof

US11795207B2 · kind B2 · utility

0Cited by
8References
26Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 30, 2021
Grant dateOct 24, 2023
Priority date—
Expiry dateJun 29, 2041

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Modified hum1.an factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, P57, L69, I80, L178, R199, H212, I215, R269, I310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.